Publications by authors named "Reshmi Roy"
Article Synopsis
- - The study aimed to assess the prevalence of ventilator-associated events (VAE) and the antibiotic resistance patterns of bacterial infections in ventilator-associated pneumonia (VAP) within an ICU in Uttarakhand, highlighting VAP as a major cause of hospital-acquired infections (HAI).
- - A total of 1,220 patients were monitored; 6.4% were diagnosed with VAE, which progressed to different infection-related conditions, with the significant presence of certain bacteria among the isolates.
- - Effective early antibiotic treatment is crucial for improving patient outcomes, with colistin being the most effective antibiotic against the detected organisms, although challenges in diagnosing VAP remain.
Nonequilibrium dynamics in Ising-like models with biased initial condition.
Phys Rev E
September 2021
We investigate the dynamical fixed points of the zero temperature Glauber dynamics in Ising-like models. The stability analysis of the fixed points in the mean field calculation shows the existence of an exponent that depends on the coordination number z in the Ising model. For the generalized voter model, a phase diagram is obtained based on this study.
View Article and Find Full Text PDFFingolimod (Gilenya) received regulatory approval from the US FDA in 2010 as the first-in-class sphingosine 1-phosphate (S1P) receptor (S1PR) modulator and was the first oral disease-modifying therapy (DMT) used for the treatment of the relapsing forms of multiple sclerosis (MS). Development of this new class of therapeutic compounds has continued to be a pharmacological goal of high interest in clinical trials for treatment of various autoimmune disorders, including MS. S1P is a physiologic signaling molecule that acts as a ligand for a group of cell surface receptors.
View Article and Find Full Text PDFPurpose: To analyze and report ToRCH-serology screening profile (Toxoplasma gondii [TOX], rubella [RV], cytomegalovirus [CMV], and herpes simplex virus [HSV-I/II]) in pediatric cataract.
Methods: In this prospective analytical study, 1,026 consecutive children were screened, of which 46 children with clinically diagnosed congenital (n = 26) and developmental cataract (n = 20) were included. Post-traumatic and familial cataracts were excluded.
Cognitive evolution in natalizumab-treated multiple sclerosis patients.
Mult Scler J Exp Transl Clin
June 2016
Background: Cognitive dysfunction affects up to 65% of multiple sclerosis (MS) patients and progresses over time. Natalizumab has been shown to be superior to placebo in preserving cognition for the first two years of therapy.
Objectives: The objectives of this study are to understand the impact of natalizumab on cognition beyond two years of therapy and to investigate whether baseline characteristics are predictive of clinical response.